We can't find the internet
Attempting to reconnect
16001.1;9 PFLS-LS
Optimization for a novel therapy targeting bacterial toxins in severe infections
Zusammenfassung
Optimization for a novel therapy targeting bacterial toxins in severe infections
Weitere Texte
Abstract
CAL02 is a non-antibiotic drug for severe bacterial infections that targets toxins and whose potency has been demonstrated in vitro and in vivo against various toxins and relevant bacterial strains. CAL02 has now been manufactured according to a new process optimized for GMP production and up-scaling. The proposed project?s objective is to optimize in vitro experiments for the validation of the GMP-enabled batch and provide key answers in order to get regulatory Scientific Advice with a view to launching a first clinical trial.
Beteiligte
Annette Draeger
Kontaktperson
draeger@ana.unibe.ch
Universität Bern Annette Draeger Baltzerstr. 2 3012 Bern BE CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2014-03-31
- Enddatum
- 2015-06-30
- Bewilligte Gesamtkosten
- CHF 73414.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Nicht aufteilbare / nicht zuteilbare Forschung
Forschungsdisziplinen
- T490 Biotechnology 100.0%